Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-30T10:43:18.585Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1454 - TMS and Negative Symptoms

Published online by Cambridge University Press:  15 April 2020

T. Wobrock ,
A. Hasan ,
P. Falkai ,
J. Cordes ,
W. Gaebel ,
B. Langguth  and
M. Landgrebe
T. Wobrock
Affiliation:
Centre of Mental Health, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany
A. Hasan
Affiliation:
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany
P. Falkai
Affiliation:
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany
J. Cordes
Affiliation:
Dept. of Psychiatry and Psychotherapy, Heinich-Heine-University Düsseldorf, Düsseldorf, Germany
W. Gaebel
Affiliation:
Dept. of Psychiatry and Psychotherapy, Heinich-Heine-University Düsseldorf, Düsseldorf, Germany
B. Langguth
Affiliation:
Dept. of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
M. Landgrebe
Affiliation:
Dept. of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

In schizophrenia negative symptoms often persist and determine an unfavourable course. Reviews including studies with small sample sizes indicate improvement of negative symptoms in schizophrenia patients by repetitive transcranial magnetic stimulation (rTMS), but provide heterogenous results. To prove the clinical efficacy of rTMS on negative symptoms trials with larger samples of patients are needed.

Methods

In a multicentre randomized, sham-controlled, rater- and patient-blind clinical trial including 197 patients we investigated the efficacy and tolerability of a 3 week 10 Hertz (Hz) rTMS add-on to antipsychotic therapy (in total 15000 stimuli, stimulation intensity 110 % of the individual motor threshold) over the left dorso-lateral prefrontal cortex (LDLPFC) immediately after treatment and during a 12 weeks follow-up.

Results

According to our primary outcome parameter we observed a significant decline in negative symptoms (negative sum score of the PANSS) in the verum and sham group (N = 124), but could not find a significant superior reduction in the verum group at day 21. At day 28 significant more patients in the verum compared to the sham group showed a clinical meaningful reduction of PANSS negative subscore (= 20 %) (N = 89; 57.5 % vs. 32.7 %, p = 0.033), however this effect did not persist at further follow-up.

Discussion

High-frequency (10 Hz) rTMS of LDLPFC over 3 weeks provided only a small benefit in the reduction of negative symptoms, however HF-rTMS was well tolerated. We discuss our results in comparison to current meta-analyses and previous studies.

Trial registration

ClinicalTrials.gov NCT00783120.

Type
W501 - New treatment options for people with schizophrenia: Focus on stimulation techniques
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.